Scholar Rock Holding Co. (NASDAQ:SRRK) Insider Jing L. Marantz Sells 5,655 Shares

Scholar Rock Holding Co. (NASDAQ:SRRK) insider Jing L. Marantz sold 5,655 shares of the business’s stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $44.20, for a total transaction of $249,951.00. Following the sale, the insider now owns 67,200 shares of the company’s stock, valued at $2,970,240. This trade represents a 7.76 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link.

Scholar Rock Price Performance

SRRK opened at $46.73 on Thursday. The firm has a market cap of $4.37 billion, a P/E ratio of -19.89 and a beta of 0.52. The company has a debt-to-equity ratio of 0.63, a quick ratio of 3.88 and a current ratio of 3.88. Scholar Rock Holding Co. has a fifty-two week low of $6.76 and a fifty-two week high of $46.81. The firm has a 50-day moving average of $40.33 and a 200 day moving average of $23.75.

Analyst Upgrades and Downgrades

SRRK has been the subject of several recent research reports. JPMorgan Chase & Co. boosted their target price on shares of Scholar Rock from $18.00 to $31.00 and gave the stock an “overweight” rating in a research report on Monday, October 14th. Truist Financial increased their price objective on Scholar Rock from $36.00 to $45.00 and gave the stock a “buy” rating in a research note on Monday, November 25th. HC Wainwright lifted their target price on Scholar Rock from $40.00 to $50.00 and gave the company a “buy” rating in a research report on Tuesday, November 26th. Wedbush restated an “outperform” rating and set a $47.00 price objective on shares of Scholar Rock in a research note on Thursday, January 9th. Finally, BMO Capital Markets boosted their price target on shares of Scholar Rock from $34.00 to $38.00 and gave the stock an “outperform” rating in a report on Friday, October 11th. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Scholar Rock has a consensus rating of “Buy” and an average price target of $40.43.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of SRRK. Rhumbline Advisers grew its holdings in Scholar Rock by 7.7% during the second quarter. Rhumbline Advisers now owns 101,278 shares of the company’s stock valued at $844,000 after purchasing an additional 7,222 shares during the period. Renaissance Technologies LLC bought a new position in shares of Scholar Rock during the 2nd quarter worth $769,000. Hsbc Holdings PLC purchased a new stake in Scholar Rock in the 2nd quarter worth about $100,000. Hood River Capital Management LLC raised its stake in Scholar Rock by 5.1% in the 2nd quarter. Hood River Capital Management LLC now owns 832,792 shares of the company’s stock valued at $6,937,000 after acquiring an additional 40,745 shares during the period. Finally, Integral Health Asset Management LLC boosted its position in Scholar Rock by 23.1% during the second quarter. Integral Health Asset Management LLC now owns 400,000 shares of the company’s stock worth $3,332,000 after purchasing an additional 75,000 shares during the period. 91.08% of the stock is owned by institutional investors.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.